<DOC>
	<DOCNO>NCT00006378</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell PURPOSE : Randomized phase II trial compare effectiveness three different regimen combine paclitaxel carboplatin plus radiation therapy treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient stage IIIA IIIB unresectable non-small cell lung cancer treat one three different combine modality regimens paclitaxel , carboplatin , radiotherapy . II . Compare safety toxicity treatment regimens patient . III . Compare relapse free survival rate patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one three treatment arm . Arm I : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 every 3 week 2 course , follow radiotherapy 5 time week 7 week begin day 42 . Arm II : Patients receive paclitaxel carboplatin arm I follow radiotherapy 5 time week , paclitaxel IV 1 hour , carboplatin IV 30 minute weekly 7 week begin day 42 . Arm III : Patients receive paclitaxel IV 1 hour carboplatin IV 30 minute weekly radiotherapy 5 time week 7 week begin day 1 , follow paclitaxel IV 3 hour carboplatin IV 30 minute every 3 week 2 course begin 3 week concurrent chemotherapy radiotherapy . Patients follow every 3 month 2 year , every 4 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 264 patient ( 88 per treatment arm ) accrue study within 20 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIA ( T12 , N2 , M0 T3 , N12 , M0 ) medically operable Stage IIIB ( T , N3 , M0 T4 , N , M0 ) Radiographic evidence mediastinal lymph node least 2.0 cm large diameter sufficient stage N2 N3 disease If large mediastinal node less 2.0 cm diameter basis stage III disease , least one node must histologically cytologically confirm positive Any follow histology allow : Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Poorly differentiate NSCLC No metastatic disease Patients tumor adjacent vertebral body allow gross disease encompass radiation boost field ( boost volume must limit less 50 % ipsilateral lung volume ) Pleural effusion transudate , cytologically negative , nonbloody allow tumor encompass within reasonable field radiotherapy Pleural effusion see chest CT chest xray small tap allow No brain metastasis MRI CT scan No prior total surgical resection PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin great 8 g/dL ( transfusion epoetin alfa allow ) Hepatic : Bilirubin le 1.5 time normal Renal : Creatinine clearance great 50 mL/min Cardiovascular : No history uncontrolled serious cardiac disease No myocardial infarction within past 6 month No congestive heart failure No unstable angina No clinically significant pericardial effusion arrhythmia Pulmonary : FEV1 great 800 mL Post obstructive pneumonia allow Other : No active concurrent prior malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix No serious medical psychiatric illness would preclude study No active serious infection No prior significant allergic reaction drug contain Cremophor ( e.g. , cyclosporine vitamin K ) No weight loss 10 % within 3 month prior diagnosis Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor ( i.e. , filgrastim ( GCSF ) sargramostim ( GMCSF ) ) No concurrent immunotherapy Concurrent epoetin alfa allow Chemotherapy : No prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal agent except nondisease relate condition ( e.g. , insulin diabetes ) Concurrent steroid administer adrenal failure septic shock allow Concurrent glucocorticosteroids antiemetic allow Radiotherapy : No prior radiotherapy thorax Surgery : See Disease Characteristics At least 3 week since formal exploratory thoracotomy recover At least 1 week since prior diagnostic thoracoscopy Other : No concurrent anticancer drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>